SC Cevostamab Highly Active in BCMA-Naive R/R Multiple Myeloma
Results from the CAMMA 3 trial showed that subcutaneous cevostamab achieved a 52.0% ORR in BCMA-naive relapsed or refractory multiple myeloma.
Why Sexual and Gender Minority Care is an Oncologic Imperative
Daniel C. McFarland, DO, and Charles S. Kamen, PhD, MPH, focused on cultural humility, nonverbal data collection, and tailored resources to improve care.
5-Year+ BRUIN Follow-Up Shows Continued Response With Pirtobrutinib in CLL/SLL
“Pirtobrutinib continues to show favorable efficacy and promising overall survival [OS],” said William G. Wierda, MD, PhD.
How to Manage Oligometastatic Kidney Cancer? Insights From IKCS 2025
Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.
Blinatumomab/Ponatinib Provides Chemo-Free Option in Ph+ ALL
Clinical efficacy and response rates were increased with blinatumomab/ponatinib vs chemotherapy/imatinib for patients with Ph+ ALL.
What Benefit Does Zanubrutinib Provide in Relapsed/Refractory CLL/SLL?
The CR/CR with incomplete bone marrow recovery rate was 12.8% in patients with relapsed/refractory CLL/SLL following zanubrutinib treatment.
